{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-26-000032","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2026-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.811145+00:00","generated_at":"2026-05-16T11:30:06.441327+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"IGC Pharma raises ~$234k in registered direct offering of 780k shares at $0.30/share","bullets":["Issued 779,997 shares of common stock at $0.30 per share for gross proceeds of ~$234k.","Offering closed on or about January 5, 2026 under existing shelf registration statement.","Net proceeds to fund working capital, clinical development, R&D, and other business initiatives."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-000032","json":"https://secwatch.observer/filing/0001185185-26-000032.json","markdown":"https://secwatch.observer/filing/0001185185-26-000032.md","text":"https://secwatch.observer/filing/0001185185-26-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000032/0001185185-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000032/igc8k010526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:30:06.441327+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a173de4b57895726be24450d5a6c145c14010d4","claim":"IGC Pharma, Inc. entered into 2025 Subscription Agreement with certain investors valued at approximately $234 thousand (effective 2026-01-05).","evidence_excerpt":"entered into a Subscription Agreement (the “2025 Subscription Agreement”) with certain investors named therein (collectively, the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering (the “Offering”), an aggregate of 779,997 shares of the Company’s common stock","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326205/000118518526000032/0001185185-26-000032-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"approximately $234 thousand"},{"label":"Effective","value":"2026-01-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}